(Reuters) – China’s National Medical Products Administration has approved domestic drugmaker Innovent Biologics’ weight control peptide injection’s entry into the market, the regulator said in a statement on Friday.
(Reporting by Beijing Newsroom; Editing by Muralikumar Anantharaman)
